<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879630</url>
  </required_header>
  <id_info>
    <org_study_id>1501531856</org_study_id>
    <nct_id>NCT02879630</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity</brief_title>
  <official_title>Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients receiving acyclovir as standard of care will be enrolled into this study. The
      currently recommended dosing strategy at our institution for obese patients is to receive
      intravenous acyclovir dosed per an adjusted body weight [IBW + 0.4(TBW-IBW)]. They will have
      blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total
      time period of 12 hours. These patients will already be hospitalized for other reasons, and
      will not be required to make additional trips to the hospital. A total of approximately 4-5
      tablespoons of blood will be drawn for this study. Ten obese patients and 10 matched control
      (non-obese) patients will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of systemic acyclovir exposure in obese and non-obese patients</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Half-life of acyclovir in obese and non-obese patients</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of acyclovir in obese and non-obese patients</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax) of acyclovir in obese and non-obese patients</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of acyclovir in obese and non-obese patients</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance of acyclovir in obese and non-obese patients</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time that concentration is above IC50 for varicella and herpes viruses in obese and non-obese patients</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese Patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese Patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Obese and non-obese patients receiving intravenous acyclovir
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥18 years of age

          -  Receiving intravenous acyclovir 5 mg/kg (TBW for normal weight patients and ABW40 for
             obese patients) as part of their routine care

          -  Weight &gt; 190% of ideal body weight (IBW) for &quot;obese&quot; patients or weight 80-120% of IBW
             for matched control patients.

        Exclusion Criteria:

          -  Receipt of acyclovir or a pro-drug of acyclovir (valacyclovir, ganciclovir,
             valganciclovir, famciclovir) in the prior 24 hours

          -  Serum creatinine &gt;1.5 mg/dL

          -  Hypersensitivity to acyclovir

          -  Patients requiring ventilator support or vasopressors in the prior 24 hours

          -  Receipt of probenecid, mycophenolate, tenofovir, or zidovudine in the prior 7 days

          -  Significant anatomical deformities that influence body habitus (i.e. amputation)

          -  Prior inclusion in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Cumpston, PharmD, BCOP</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pam Bunner</last_name>
    <phone>304-598-4511</phone>
    <email>bunnerp@wvumedicine.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Bunner</last_name>
      <phone>304-598-4511</phone>
      <email>bunnerp@wvumedicine.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2016</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Aaron Cumpston, PharmD, BCOP</investigator_full_name>
    <investigator_title>Pharmacy Clinical Specialist</investigator_title>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>acyclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

